Who Owns Takeda Pharmaceutical Co Ltd
Every manager with more than $100m in listed equities files a 13F each quarter naming what they hold. These are the ones reporting a position in Takeda Pharmaceutical Co Ltd.
Who crossed 5% of TAK →Positions as of 2026-09-30
Largest first. The move is against the previous quarter that manager filed, not the previous calendar quarter.
| Manager | Value |
|---|---|
| Legacy Wealth Asset Management, LLCSPONSORED ADS166.7K shadded | $3M |
| Farther Finance Advisors, LLCADR25.4K shadded | $462.4K |
| GAMMA Investing LLCADR17.4K shadded | $316.5K |
| Valeo Financial Advisors, LLCADR12.9K shadded | $235.1K |
| RIVERSEDGE ADVISORS, LLCSPONSORED ADS11.7K sh— | $212K |
| Rosenberg Matthew HamiltonADR1.1K shtrimmed | $20.5K |
| Marquette Asset Management, LLCSPONSORED ADS1K sh— | $18.2K |
| ELEVATION WEALTH PARTNERS, LLCSPONSORED ADS693 shheld | $12.6K |
| Retirement Wealth Solutions LLCSPONSORED ADS473 shadded | $8.6K |
| Bangor Savings BankSPONSORED ADS186 shheld | $3.4K |
| Trust CoADR64 shheld | $1.2K |
| Bullock Wealth Management GroupADR30 shheld | $536 |
| GILPIN WEALTH MANAGEMENT, LLCSPONSORED ADS16 sh— | $292 |
Source: quarterly 13F filings, via EDGAR. A 13F reports positions by CUSIP alone; each CUSIP here has been confirmed against OpenFIGI rather than matched by name, because a name match would attribute one company's shareholders to another. Positions are as of quarter end and can be months old by the time they are filed, and 13F covers long equity positions only — not shorts, and not most debt. The summed value is what these filers reported, not the company's institutional ownership.
More on TAK
Follow Takeda Pharmaceutical Co Ltd (TAK) by email
New trades in Takeda Pharmaceutical Co Ltd (TAK) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.